EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Translational pathways for MSC secretome therapies: from bioprocessing to delivery

Maria Rossello-Gelabert, Natalia Escacena, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez

Trends in Biotechnology · 2026-08 · 44 (8) · 2279-2296

DOI: 10.1016/j.tibtech.2025.12.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2026-08. Verfasst von Maria Rossello-Gelabert und 4 weiteren Autor:innen. Beteiligte Einrichtung: NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, Vi…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Secretome, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: Basque Government, Agencia Estatal de Investigación, Gobierno de España Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesenchymal stromal cells (MSCs) are multipotent, fibroblast-like cells known for their paracrine activity rather than long-term engraftment. Their secretome-the ensemble of soluble factors and extracellular vesicles released by these cells-is emerging as a designable, off-the-shelf biotherapeutic. Advances in scalable bioprocessing, closed downstream processing, and smart delivery enable good manufacturing practice-ready translation. This review outlines a product-focused road map linking cell sourcing, preconditioning, and bioreactor expansion with downstream processing steps. We highlight bottlenecks, including heterogeneity, stability, dose definition, and validated potency assays, and address regulatory implications for classification, comparability, and release. By reframing the MSC secretome as a manufactured product rather than a biological extract, we propose strategies to speed clinical readiness and establish it as a reproducible next-generation biotherapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsSecretomeMesenchymal Stem Cell TransplantationHumansBioreactorsAnimalsCell Culture Techniques

Stichwörter der Autor:innen

biomanufacturingclinical translationdeliveryformulationmesenchymal stromal cells (MSCs)secretome

Autor:innen und Institutionen

  • NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, Vitoria Gasteiz 01006, Spain; Bioaraba, NanoBioCel Research Group, Vitor…
  • Regulatory Affairs Consultant, Seville, Spain.
  • NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, Vitoria Gasteiz 01006, Spain; Biomedical Research Networking Centre in B…

Förderung

  • Basque Government
  • Agencia Estatal de Investigación
  • Gobierno de España Ministerio de Ciencia e Innovación
  • European Social Fund
  • European Regional Development Fund

Zitieren

APA

Rossello-Gelabert, M., Escacena, N., Igartua, M., Santos-Vizcaino, E., & Hernandez, R. M. (2026). Translational pathways for MSC secretome therapies: from bioprocessing to delivery. Trends in Biotechnology, 44(8), 2279-2296. https://doi.org/10.1016/j.tibtech.2025.12.003

Vancouver

Rossello-Gelabert M, Escacena N, Igartua M, Santos-Vizcaino E, Hernandez RM. Translational pathways for MSC secretome therapies: from bioprocessing to delivery. Trends in Biotechnology. 2026;44(8):2279-2296. doi:10.1016/j.tibtech.2025.12.003

BibTeX
@article{RosselloGelabert2026,
  author = {Rossello-Gelabert, Maria and Escacena, Natalia and Igartua, Manoli and Santos-Vizcaino, Edorta and Hernandez, Rosa Maria},
  title = {Translational pathways for MSC secretome therapies: from bioprocessing to delivery},
  journal = {Trends in Biotechnology},
  year = {2026},
  volume = {44},
  number = {8},
  pages = {2279--2296},
  doi = {10.1016/j.tibtech.2025.12.003}
}
Kostenlos starten →